Staff directory Muriel Freixanet Gusta

Muriel Freixanet Gusta

Research Support Technician
muriel.freixanet(ELIMINAR)@icn2.cat
Inorganic Nanoparticles

Publications

2024

  • Long-Term Intracellular Tracking of Label-Free Nanoparticles in Live Cells and Tissues with Confocal Microscopy

    Gusta, Muriel F; Ernst, Lena M; Moriones, Oscar H; Piella, Jordi; Valeri, Marta; Bastus, Neus G; Puntes, Victor Small Methods; 2024. 10.1002/smtd.202301713.

2023

  • In Vitro Antibacterial Activity of Silver Nanoparticles Conjugated with Amikacin and Combined with Hyperthermia against Drug-Resistant and Biofilm-Producing Strains

    Palau, M; Muñoz, E; Gusta, MF; Larrosa, N; Gomis, X; Gilabert, J; Almirante, B; Puntes, V; Texidó, R; Gavaldà, J Microbiology Spectrum; 11 (3): e0028023. 2023. 10.1128/spectrum.00280-23. IF: 3.700

  • Exploiting endocytosis for transfection of mRNA for cytoplasmatic delivery using cationic gold nanoparticles

    Gustà, MF; Edel, MJ; Salazar, VA; Alvarez-Palomo, B; Juan, M; Broggini, M; Damia, G; Bigini, P; Corbelli, A; Fiordaliso, F; Barbul, A; Korenstein, R; Bastús, NG; Puntes, V Frontiers In Immunology; 14: 1128582. 2023. 10.3389/fimmu.2023.1128582. IF: 7.300

  • Exploring the Long-Term Tissue Accumulation and Excretion of 3 nm Cerium Oxide Nanoparticles after Single Dose Administration

    Ernst, LM; Mondragón, L; Ramis, J; Gustà, MF; Yudina, T; Casals, E; Bastús, NG; Fernández-Varo, G; Casals, G; Jiménez, W; Puntes, V Antioxidants; 12 (3): 765. 2023. 10.3390/antiox12030765. IF: 7.000

2022

  • Role of Common Cell Culture Media Supplements on Citrate-Stabilized Gold Nanoparticle Protein Corona Formation, Aggregation State, and the Consequent Impact on Cellular Uptake

    Barbero F., Michelini S., Moriones O.H., Patarroyo J., Rosell J., F. Gusta M., Vitali M., Martín L., Canals F., Duschl A., Horejs-Hoeck J., Mondragón L., Bastús N.G., Puntes V. Bioconjugate Chemistry; 33 (8): 1505 - 1514. 2022. 10.1021/acs.bioconjchem.2c00232.

    Sodium citrate-stabilized gold nanoparticles (AuNPs) are destabilized when dispersed in cell culture media (CCMs). This may promote their aggregation and subsequent sedimentation, or under the proper conditions, their interaction with dispersed proteins can lead to the formation of a NP-stabilizing protein corona. CCMs are ionic solutions that contain growth substances which are typically supplemented, in addition to serum, with different substances such as dyes, antioxidants, and antibiotics. In this study, the impact of phenol red, penicillin-streptomycin, l-glutamine, and β-mercaptoethanol on the formation of the NP-protein corona in CCMs was investigated. Similar protein coronas were obtained except in the presence of antibiotics. Under these conditions, the protein corona took more time to be formed, and its density and composition were altered, as indicated by UV-vis spectroscopy, Z potential, dynamic light scattering, and liquid chromatography-mass spectrometry analyses. As a consequence of these modifications, a significantly different AuNP cellular uptake was measured, showing that NP uptake increased as did the NP aggregate formation. AuNP uptake studies performed in the presence of clathrin- and caveolin-mediated endocytosis inhibitors showed that neither clathrin receptors nor lipid rafts were significantly involved in the internalization mechanism. These results suggest that in these conditions, NP aggregation is the main mechanism responsible for their cellular uptake. © 2022 American Chemical Society.

    View abstract

2020

  • Epigenetics in breast cancer therapy—New strategies and future nanomedicine perspectives

    Buocikova V., Rios-Mondragon I., Pilalis E., Chatziioannou A., Miklikova S., Mego M., Pajuste K., Rucins M., Yamani N.E., Longhin E.M., Sobolev A., Freixanet M., Puntes V., Plotniece A., Dusinska M., Cimpan M.R., Gabelova A., Smolkova B. Cancers; 12 (12, 3622): 1 - 32. 2020. 10.3390/cancers12123622. IF: 6.126

    Epigenetic dysregulation has been recognized as a critical factor contributing to the development of resistance against standard chemotherapy and to breast cancer progression via epithelial-to-mesenchymal transition. Although the efficacy of the first-generation epigenetic drugs (epi-drugs) in solid tumor management has been disappointing, there is an increasing body of evidence showing that epigenome modulation, in synergy with other therapeutic approaches, could play an important role in cancer treatment, reversing acquired therapy resistance. However, the epigenetic therapy of solid malignancies is not straightforward. The emergence of nanotechnologies applied to medicine has brought new opportunities to advance the targeted delivery of epi-drugs while improving their stability and solubility, and minimizing off-target effects. Furthermore, the omics technologies, as powerful molecular epidemiology screening tools, enable new diagnostic and prognostic epigenetic biomarker identification, allowing for patient stratification and tailored management. In combination with new-generation epi-drugs, nanomedicine can help to overcome low therapeutic efficacy in treatment-resistant tumors. This review provides an overview of ongoing clinical trials focusing on combination therapies employing epi-drugs for breast cancer treatment and summarizes the latest nano-based targeted delivery approaches for epi-drugs. Moreover, it highlights the current limitations and obstacles associated with applying these experimental strategies in the clinics. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.

    View abstract